Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).  
News | Drug-Eluting Balloons | November 03, 2020
FDA Clears Boston Scientific Ranger Drug-coated Balloon
November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated...
read more
News | Robotic Systems | November 03, 2020
Robocath Enters Joint Venture With MicroPort to Commercialize Cath Lab Robotic System in China
November 3, 2020 – Robocath, a company commercializing cardiovascular cath lab robotic systems, announced creation of...
read more
The American Heart Association, AHA, late-breaking sessions, trials, studies. #AHA #AHA20 #AHA2020
Feature | AHA | November 20, 2020 | Dave Fornell, Editor
American Heart Association 2020 Late-breaking Trial Presentations 
Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual...
read more
Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare. #TCT #TCT2020 #TCTconnect

Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare

Feature | FFR Technologies | October 30, 2020 | Dave Fornell, Editor
FFR Studies Find Several Surprises at TCT 2020
Fractional flow reserve (FFR) is considered the gold standard measure whether a coronary lesions needs a percutaneous...
read more
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.

Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Top 10 Takeaways on Interventional Technologies at TCT 2020
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials...
read more
The Watchman FLX will be tested in the CHAMPION-AF trial looks at next-generation transcatheter LAA device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation.
News | Atrial Fibrillation | October 29, 2020
Boston Scientific Initiates Trial to Evaluate Watchman FLX LAA Closure Device as First-Line Treatment
Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the...
read more
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 
Feature | ECMO Systems | October 26, 2020
FDA Clears Abiomed Compact ECMO System for COVID-19 and Cardiogenic Shock Patients
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-...
read more
Abre venous self-expanding stent found safe, effective in treating challenging deep venous lesions was approved by the FDA.
News | Venous Therapies | October 26, 2020
Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding...
read more
Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system. #TCT2020 #TCTconnect

Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system.
 

News | Pulmonary Embolism | October 23, 2020
Acute Hemodynamic Improvement With Percutaneous Mechanical Thrombectomy in a Real-world Pulmonary Embolism Population
October 23, 2020 —  Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world...
read more
Example of FFR assessment of the coronary hemodynamic flow in lesions using the Philips FFR, iFR assessment system. #FFR #TCTconnect #TCT2020

FFR assessment of a coronary lesion using the Philips Healthcare Volcano FFR system.

News | FFR Technologies | October 23, 2020
Deferring PCI in FFR-Abnormal Lesions With Preserved Coronary Flow Reserve Not Associated With Similar Outcomes as Untreated Lesions with Normal FFR
October 23, 2020 – A new observational study of deferred lesions following combined fractional flow reserve (FFR) and...
read more
Fractional Flow reserve (FFR) selection on the Abbott, St. Jude FFR system console. The TARGET FFR study at #TCT2020 #TCTconnect.
News | FFR Technologies | October 23, 2020
FFR-guided PCI Optimization Strategy May Lead to Improved Outcomes
October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided...
read more
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone actually was not flow limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings. #TCT2020 #TCTconnect

An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

News | FFR Technologies | October 22, 2020 | Dave Fornell, Editor
FFR-CT Did Not Significantly Reduce Costs But Reduced Rates of Invasive Coronary Angiography
October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from...
read more
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates.

Feature | Stents | October 22, 2020 | Dave Fornell, Editor
Durable Polymer Drug-Eluting Stents Perform Better Than Biodegradable Polymer DES
October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable...
read more
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents | October 22, 2020
Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events
October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology...
read more
Videos | Coronavirus (COVID-19) | October 20, 2020
VIDEO: Use of Impella in COVID-19 Patients
Chuck Simonton, M.D., chief medical officer at Abiomed, explains when advanced hemodynamic support in required in COVID...
read more
© Copyright Wainscot Media. All Rights Reserved.